Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
155.29
+0.51 (0.33%)
Nov 12, 2026, 2:04 PM EST - Market open
Guardant Health Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,279 | 982.02 | 739.02 | 563.95 | 449.54 | 373.65 |
Revenue Growth | 41.69% | 32.88% | 31.04% | 25.45% | 20.31% | 30.31% |
Gross Profit Gross Profit Growth | 833.7 | 633.01 | 449.22 | 336.9 | 293.21 | 250.74 |
Operating Income Operating Income Growth | -503.92 | -436.3 | -442.58 | -481.22 | -544.38 | -411 |
Net Income Net Income Growth | -485.07 | -416.28 | -436.37 | -479.45 | -654.59 | -405.67 |
Earnings Per Share EPS Growth | -3.68 | -3.32 | -3.56 | -4.28 | -6.41 | -4.00 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Oncology Oncology Growth | 845.27 | 683.6 | 542.83 | 403.88 |
Biopharma and Data Biopharma and Data Growth | 226.9 | 210.13 | 177.58 | 136.35 |
Screening Screening Growth | 197.2 | 79.73 | 5.12 | - |
Licensing and Other Licensing and Other Growth | 9.51 | 8.56 | 13.49 | 23.72 |
Revenue (Total) Revenue (Total) Growth | 1,279 | 982.02 | 739.02 | 563.95 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,027 | 1,202 | 839.98 | 1,169 | 1,011 | 1,631 |
Total Debt Total Debt Growth | 1,691 | 1,710 | 1,336 | 1,354 | 1,369 | 1,374 |
Net Cash (Debt) Net Cash Growth | -664.59 | -508.54 | -496.07 | -185.13 | -358.05 | 257.05 |
Net Cash Growth | - | - | - | - | - | -78.34% |
Net Cash Per Share Net Cash Per Share Growth | -5.04 | -4.06 | -4.04 | -1.65 | -3.50 | 2.54 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -173.48 | -184.76 | -239.86 | -324.98 | -309.46 | -209.02 |
Capital Expenditures CapEx Growth | -58.67 | -48.31 | -35.09 | -20.49 | -77.46 | -75.04 |
Free Cash Flow Free Cash Flow Growth | -232.15 | -233.07 | -274.94 | -345.46 | -386.92 | -284.05 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 65.19% | 64.46% | 60.79% | 59.74% | 65.22% | 67.11% |
Operating Margin | -39.40% | -44.43% | -59.89% | -85.33% | -121.10% | -110.00% |
Pretax Margin | -37.99% | -42.52% | -58.87% | -84.90% | -145.36% | -102.89% |
Profit Margin | -37.93% | -42.39% | -59.05% | -85.02% | -145.61% | -108.57% |
FCF Margin | -18.15% | -23.73% | -37.20% | -61.26% | -86.07% | -76.02% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 16.54 | 13.40 | 5.11 | 5.82 | 6.20 | 27.21 |